U.S. Stem Cell, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 06, 2019 at 04:43 pm EST
Share
U.S. Stem Cell, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 156,591 compared to USD 1.503 million a year ago. Operating loss was USD 1.597 million compared to USD 218,751 a year ago. Net loss was USD 1.645 million compared to USD 330,937 a year ago. For the nine months, total revenue was USD 2.763 million compared to USD 5.037 million a year ago. Operating loss was USD 2.530 million compared to USD 1.051 million a year ago. Net loss was USD 3.158 million compared to USD 1.714 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to Basic EPS - Continuing Operations of USD 0 a year ago.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
U.S. STEM CELL, INC. 
